Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.87% | -4.18% | -5.34% | -12.15% | -6.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.87% | -4.18% | -5.34% | -12.15% | -6.71% |
| Cost of Revenue | -8.54% | -6.59% | -5.70% | -10.18% | -0.96% |
| Gross Profit | 1.32% | -2.40% | -5.09% | -13.53% | -10.53% |
| SG&A Expenses | 3.88% | -3.76% | -9.84% | -12.70% | -9.80% |
| Depreciation & Amortization | 42.01% | 23.63% | 5.94% | -0.47% | -3.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.74% | -3.85% | -8.19% | -12.23% | -6.61% |
| Operating Income | -31.25% | -6.77% | 17.57% | -11.52% | -7.47% |
| Income Before Tax | -86.19% | 1,258.49% | 465.71% | 246.00% | 143.07% |
| Income Tax Expenses | -2,270.00% | -352.19% | 94.48% | 86.86% | 100.51% |
| Earnings from Continuing Operations | -26.19% | 1,150.00% | -39.42% | -53.23% | -66.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.19% | 1,150.00% | -39.42% | -53.23% | -66.61% |
| EBIT | -31.25% | -6.77% | 17.57% | -11.52% | -7.47% |
| EBITDA | -7.29% | 3.32% | 14.33% | -8.17% | -6.08% |
| EPS Basic | -11.52% | 882.79% | -51.61% | -62.17% | -78.32% |
| Normalized Basic EPS | -12.44% | 144.47% | 1,136.04% | 1,021.71% | 251.18% |
| EPS Diluted | -11.52% | 763.19% | -44.71% | -55.41% | -71.15% |
| Normalized Diluted EPS | -12.44% | 144.47% | 1,120.50% | 1,006.18% | 250.36% |
| Average Basic Shares Outstanding | 18.78% | 15.67% | 15.74% | 21.08% | 16.64% |
| Average Diluted Shares Outstanding | 18.78% | 15.67% | 12.83% | 17.88% | 13.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |